Eli Lilly Profit Rises, Helped by Covid-19 Drug Sales

Antibody drug bamlanivimab brought in world-wide revenue of $871.2 million, contributing much of the company’s 22% revenue growth in the fourth quarter of 2020.Antibody drug bamlanivimab brought in world-wide revenue of $871.2 million, contributing much of the company’s 22% revenue growth in the fourth quarter of 2020.Read MorePAIDWSJ.com: US Business